Bender Robert & Associates Decreased Celgene (CELG) Position; Shorts at Compugen Limited (CGEN) Raised By 8.31%

February 20, 2018 - By Richard Conner

Compugen Limited (NASDAQ:CGEN) had an increase of 8.31% in short interest. CGEN’s SI was 2.27M shares in February as released by FINRA. Its up 8.31% from 2.10M shares previously. With 136,900 avg volume, 17 days are for Compugen Limited (NASDAQ:CGEN)’s short sellers to cover CGEN’s short positions. The SI to Compugen Limited’s float is 4.93%. The stock increased 3.33% or $0.1 during the last trading session, reaching $3.1. About 140,065 shares traded. Compugen Ltd. (NASDAQ:CGEN) has declined 29.94% since February 20, 2017 and is downtrending. It has underperformed by 46.64% the S&P500.

Bender Robert & Associates decreased Celgene Corp (CELG) stake by 5.78% reported in 2017Q3 SEC filing. Bender Robert & Associates sold 4,873 shares as Celgene Corp (CELG)’s stock declined 3.49%. The Bender Robert & Associates holds 79,378 shares with $11.58 million value, down from 84,251 last quarter. Celgene Corp now has $71.65B valuation. The stock decreased 0.92% or $0.88 during the last trading session, reaching $95.26. About 5.78 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since February 20, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company has market cap of $158.55 million. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. It currently has negative earnings. The Company’s antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target.

Among 5 analysts covering Compugen (NASDAQ:CGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Compugen had 8 analyst reports since August 5, 2015 according to SRatingsIntel. Zacks upgraded Compugen Ltd. (NASDAQ:CGEN) on Wednesday, September 2 to “Hold” rating. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 5. The stock has “Sell” rating by Zacks on Friday, August 21. JMP Securities maintained it with “Market Outperform” rating and $11 target in Wednesday, March 9 report. FBR Capital initiated the shares of CGEN in report on Thursday, October 15 with “Outperform” rating. Cowen & Co initiated Compugen Ltd. (NASDAQ:CGEN) rating on Thursday, October 15. Cowen & Co has “Outperform” rating and $14 target. As per Wednesday, August 5, the company rating was maintained by MLV.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 2 Sell and 12 Hold. Therefore 58% are positive. Celgene Corporation had 132 analyst reports since July 21, 2015 according to SRatingsIntel. Mizuho maintained the shares of CELG in report on Wednesday, July 26 with “Buy” rating. SunTrust maintained it with “Buy” rating and $127.0 target in Monday, January 8 report. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Monday, July 10 by Jefferies. Bank of America downgraded Celgene Corporation (NASDAQ:CELG) rating on Friday, January 5. Bank of America has “Hold” rating and $120.0 target. As per Tuesday, August 22, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating given on Thursday, October 19 by RBC Capital Markets. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, April 19. The firm has “Buy” rating given on Thursday, September 14 by Jefferies. The stock has “Market Perform” rating by Bernstein on Wednesday, December 27. Leerink Swann maintained it with “Buy” rating and $156.0 target in Friday, October 20 report.

Since September 5, 2017, it had 1 insider buy, and 3 selling transactions for $2.54 million activity. $1.29M worth of stock was sold by CASEY MICHAEL D on Tuesday, September 5. $299,594 worth of stock was bought by Alles Mark J on Thursday, February 8. 9,250 shares valued at $1.31M were sold by KAPLAN GILLA on Tuesday, September 12. Another trade for 1,727 shares valued at $248,498 was made by Curran Terrie on Monday, September 25.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: